A number of new investigational studies in diabetes are being launched by the UCSF Pediatric Diabetes Clinical Research Program under the leadership of Steve Gitelman, MD. Investigational studies are studies that are not approved for use in diabetes by the U.S. Food and Drug Administration.
One investigational study involves regulatory T cells (Tregs). This study will support a future study that will test if Tregs can stop the destruction of the insulin producing cells in people diagnosed with type 1 diabetes within the last 2 years.
A second investigational study explores if a combination therapy (Thymoglobulin® + Neulasta®), can be used as a possible treatment for those who have established type 1 diabetes. The secondary purpose is to determine if giving Thymoglobulin® + Neulasta® to patients with established type 1 diabetes will preserve insulin production. Thymoglobulin® is approved for treating organ transplant rejection in kidney transplant patients. Neulasta® is approved for treating patients receiving cancer therapy.